![]() |
市場調查報告書
商品編碼
1727686
細胞治療的共同研究及授權契約:2016年~2025年Cell Therapy Collaboration and Licensing Deals 2016-2025 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
"細胞療法合作與許可交易" 報告提供了前所未有的途徑,讓我們能夠全面了解全球領先生物製藥公司簽署的細胞療法交易。
本報告詳細介紹了2016年至2025年的細胞療法交易,並詳細分析了企業達成細胞療法交易的方式和原因。這些交易通常包含多個環節,從合作研發到成果商業化。
本報告涵蓋合作、開發、研究和授權交易,並包含自2016年以來宣布的989項細胞療法交易的完整清單。此外,報告還包含本公司及其合作夥伴向美國證券交易委員會提交的合約文件(如有)。
本報告的第一章介紹了細胞療法交易。
第一章是對報告的介紹。
第2章概述了自2016年以來的細胞療法交易活動。
第3章概述了自2016年以來的主要細胞療法交易。交易按總價值列出。
第4章列出了在細胞療法交易中最活躍的25家公司,隨後進行了簡要總結,並提供了完整的細胞療法交易清單和公開的合約文件。
第5章全面深入地回顧了自2016年1月以來已完成和宣布的細胞療法交易,重點介紹了已公開合約文件的交易。
第6章全面深入地回顧了自2016年1月以來已完成和宣布的細胞療法合作計畫。本章按感興趣的特定細胞療法技術類型進行組織。
該報告還包含大量圖表和數據,展現了自2016年以來細胞療法交易活動和趨勢。
此外,綜合交易目錄依公司A-Z、交易類型及治療目標進行整理。每個交易標題都透過網頁連結連結到線上交易記錄,並在可用的地方包含合約文件,方便您隨時存取每份協議文件。
"細胞療法合作與授權協議" 一書提供讀者以下主要優勢:
細胞療法合作與許可交易包括:
分析合約文件有助於進行以下方面的盡職調查:
Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 989 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of cell therapy dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.
Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:
Cell Therapy Collaboration and Licensing Deals includes:
Analyzing contract agreements allows due diligence of: